A positive-margin resection model recreates the postsurgical tumor microenvironment and is a reliable model for adjuvant therapy evaluation

References

• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69 - 90; http://dx.doi.org/10.3322/caac.20107; PMID: 21296855
   PubMed Web of Science ®Google Scholar
• Predina JD, Judy B, Aliperti LA, Fridlender ZG, Blouin A, Kapoor V, et al. Neoadjuvant in situ gene-mediated cytotoxic immunotherapy improves postoperative outcomes in novel syngeneic esophageal carcinoma models. Cancer Gene Ther 2011; 18:871 - 83; http://dx.doi.org/10.1038/cgt.2011.56; PMID: 21869822
   PubMed Web of Science ®Google Scholar
• Roh JL, Sung MW, Park SW, Heo DS, Lee DW, Kim KH. Celecoxib can prevent tumor growth and distant metastasis in postoperative setting. Cancer Res 2004; 64:3230 - 5; http://dx.doi.org/10.1158/0008-5472.CAN-03-3050; PMID: 15126364
   PubMed Web of Science ®Google Scholar
• Schultz GS, White M, Mitchell R, Brown G, Lynch J, Twardzik DR, et al. Epithelial wound healing enhanced by transforming growth factor-alpha and vaccinia growth factor. Science 1987; 235:350 - 2; http://dx.doi.org/10.1126/science.3492044; PMID: 3492044
   PubMed Web of Science ®Google Scholar
• Schreiber K, Rowley DA, Riethmüller G, Schreiber H. Cancer immunotherapy and preclinical studies: why we are not wasting our time with animal experiments. Hematol Oncol Clin North Am 2006; 20:567 - 84; http://dx.doi.org/10.1016/j.hoc.2006.03.001; PMID: 16762725
   PubMed Web of Science ®Google Scholar
• Smith MJ, Culhane AC, Killeen S, Kelly MA, Wang JH, Cotter TG, et al. Mechanisms driving local breast cancer recurrence in a model of breast-conserving surgery. Ann Surg Oncol 2008; 15:2954 - 64; http://dx.doi.org/10.1245/s10434-008-0037-5; PMID: 18622646
   PubMed Web of Science ®Google Scholar
• Grinshtein N, Bridle B, Wan Y, Bramson JL. Neoadjuvant vaccination provides superior protection against tumor relapse following surgery compared with adjuvant vaccination. Cancer Res 2009; 69:3979 - 85; http://dx.doi.org/10.1158/0008-5472.CAN-08-3385; PMID: 19383917
   PubMed Web of Science ®Google Scholar
• Broomfield S, Currie A, van der Most RG, Brown M, van Bruggen I, Robinson BW, et al. Partial, but not complete, tumor-debulking surgery promotes protective antitumor memory when combined with chemotherapy and adjuvant immunotherapy. Cancer Res 2005; 65:7580 - 4; PMID: 16140921
   PubMed Web of Science ®Google Scholar
• DeLisser HM, Keirns CC, Clinton EA, Margolis ML. “The air got to it:” exploring a belief about surgery for lung cancer. J Natl Med Assoc 2009; 101:765 - 71; PMID: 19715038
   PubMed Web of Science ®Google Scholar
• Stuelten CH, Barbul A, Busch JI, Sutton E, Katz R, Sato M, et al. Acute wounds accelerate tumorigenesis by a T cell-dependent mechanism. Cancer Res 2008; 68:7278 - 82; http://dx.doi.org/10.1158/0008-5472.CAN-08-1842; PMID: 18794114
   PubMed Web of Science ®Google Scholar
• Rofstad EK, Mathiesen B, Henriksen K, Kindem K, Galappathi K. The tumor bed effect: increased metastatic dissemination from hypoxia-induced up-regulation of metastasis-promoting gene products. Cancer Res 2005; 65:2387 - 96; http://dx.doi.org/10.1158/0008-5472.CAN-04-3039; PMID: 15781654
   PubMed Web of Science ®Google Scholar
• Alsousou J, Thompson M, Hulley P, Noble A, Willett K. The biology of platelet-rich plasma and its application in trauma and orthopaedic surgery: a review of the literature. J Bone Joint Surg Br 2009; 91:987 - 96; http://dx.doi.org/10.1302/0301-620X.91B8.22546; PMID: 19651823
   PubMed Web of Science ®Google Scholar
• Suzuki E, Kapoor V, Cheung HK, Ling LE, DeLong PA, Kaiser LR, et al. Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity. Clin Cancer Res 2004; 10:5907 - 18; http://dx.doi.org/10.1158/1078-0432.CCR-03-0611; PMID: 15355924
   PubMed Web of Science ®Google Scholar
• Suzuki E, Kim S, Cheung HK, Corbley MJ, Zhang X, Sun L, et al. A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection. Cancer Res 2007; 67:2351 - 9; http://dx.doi.org/10.1158/0008-5472.CAN-06-2389; PMID: 17332368
   PubMed Web of Science ®Google Scholar
• Ueda R, Fujita M, Zhu X, Sasaki K, Kastenhuber ER, Kohanbash G, et al. Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines. Clin Cancer Res 2009; 15:6551 - 9; http://dx.doi.org/10.1158/1078-0432.CCR-09-1067; PMID: 19861464
   PubMed Web of Science ®Google Scholar
• Kim S, Buchlis G, Fridlender ZG, Sun J, Kapoor V, Cheng G, et al. Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy. Cancer Res 2008; 68:10247 - 56; http://dx.doi.org/10.1158/0008-5472.CAN-08-1494; PMID: 19074893
   PubMed Web of Science ®Google Scholar
• Lee GT, Hong JH, Kwak C, Woo J, Liu V, Lee C, et al. Effect of dominant negative transforming growth factor-beta receptor type II on cytotoxic activity of RAW 264.7, a murine macrophage cell line. Cancer Res 2007; 67:6717 - 24; http://dx.doi.org/10.1158/0008-5472.CAN-06-4263; PMID: 17638882
   PubMed Web of Science ®Google Scholar
• Terabe M, Ambrosino E, Takaku S, O’Konek JJ, Venzon D, Lonning S, et al. Synergistic enhancement of CD8+ T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-beta monoclonal antibody. Clin Cancer Res 2009; 15:6560 - 9; http://dx.doi.org/10.1158/1078-0432.CCR-09-1066; PMID: 19861451
   PubMed Web of Science ®Google Scholar
• Fontana A, Galli L, Fioravanti A, Orlandi P, Galli C, Landi L, et al. Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer. Clin Cancer Res 2009; 15:4954 - 62; http://dx.doi.org/10.1158/1078-0432.CCR-08-3317; PMID: 19622584
   PubMed Web of Science ®Google Scholar
• Hahn T, Alvarez I, Kobie JJ, Ramanathapuram L, Dial S, Fulton A, et al. Short-term dietary administration of celecoxib enhances the efficacy of tumor lysate-pulsed dendritic cell vaccines in treating murine breast cancer. Int J Cancer 2006; 118:2220 - 31; http://dx.doi.org/10.1002/ijc.21616; PMID: 16331615
   PubMed Web of Science ®Google Scholar
• Howe LR, Subbaramaiah K, Patel J, Masferrer JL, Deora A, Hudis C, et al. Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res 2002; 62:5405 - 7; PMID: 12359744
   PubMed Web of Science ®Google Scholar
• Haas AR, Sun J, Vachani A, Wallace AF, Silverberg M, Kapoor V, et al. Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine. Clin Cancer Res 2006; 12:214 - 22; http://dx.doi.org/10.1158/1078-0432.CCR-05-1178; PMID: 16397045
   PubMed Web of Science ®Google Scholar
• Kruklitis RJ, Singhal S, Delong P, Kapoor V, Sterman DH, Kaiser LR, et al. Immuno-gene therapy with interferon-beta before surgical debulking delays recurrence and improves survival in a murine model of malignant mesothelioma. J Thorac Cardiovasc Surg 2004; 127:123 - 30; http://dx.doi.org/10.1016/j.jtcvs.2003.08.034; PMID: 14752422
   PubMed Web of Science ®Google Scholar
• Bursuker I, North RJ. Generation and decay of the immune response to a progressive fibrosarcoma. II. Failure to demonstrate postexcision immunity after the onset of T cell-mediated suppression of immunity. J Exp Med 1984; 159:1312 - 21; http://dx.doi.org/10.1084/jem.159.5.1312; PMID: 6232336
   PubMed Web of Science ®Google Scholar
• Shakhar G, Ben-Eliyahu S. Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients?. Ann Surg Oncol 2003; 10:972 - 92; http://dx.doi.org/10.1245/ASO.2003.02.007; PMID: 14527919
   PubMed Web of Science ®Google Scholar
• Hoffman RM. The multiple uses of fluorescent proteins to visualize cancer in vivo. Nat Rev Cancer 2005; 5:796 - 806; http://dx.doi.org/10.1038/nrc1717; PMID: 16195751
   PubMed Web of Science ®Google Scholar
• Kishimoto H, Zhao M, Hayashi K, Urata Y, Tanaka N, Fujiwara T, et al. In vivo internal tumor illumination by telomerase-dependent adenoviral GFP for precise surgical navigation. Proc Natl Acad Sci U S A 2009; 106:14514 - 7; http://dx.doi.org/10.1073/pnas.0906388106; PMID: 19706537
   PubMed Web of Science ®Google Scholar
• Teicher BA. Transforming growth factor-beta and the immune response to malignant disease. Clin Cancer Res 2007; 13:6247 - 51; http://dx.doi.org/10.1158/1078-0432.CCR-07-1654; PMID: 17975134
   PubMed Web of Science ®Google Scholar
• Yang L, Pang Y, Moses HL. TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol 2010; 31:220 - 7; http://dx.doi.org/10.1016/j.it.2010.04.002; PMID: 20538542
   PubMed Web of Science ®Google Scholar
• Wallace A, Kapoor V, Sun J, Mrass P, Weninger W, Heitjan DF, et al. Transforming growth factor-beta receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers. Clin Cancer Res 2008; 14:3966 - 74; http://dx.doi.org/10.1158/1078-0432.CCR-08-0356; PMID: 18559619
   PubMed Web of Science ®Google Scholar
• Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. Cancer Cell 2009; 16:183 - 94; http://dx.doi.org/10.1016/j.ccr.2009.06.017; PMID: 19732719
   PubMed Web of Science ®Google Scholar
• DeLong P, Tanaka T, Kruklitis R, Henry AC, Kapoor V, Kaiser LR, et al. Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapy. Cancer Res 2003; 63:7845 - 52; PMID: 14633712
   PubMed Web of Science ®Google Scholar
• Tanaka T, Delong PA, Amin K, Henry A, Kruklitis R, Kapoor V, et al. Treatment of lung cancer using clinically relevant oral doses of the cyclooxygenase-2 inhibitor rofecoxib: potential value as adjuvant therapy after surgery. Ann Surg 2005; 241:168 - 78; PMID: 15622005
   PubMed Web of Science ®Google Scholar
• Kim SK, Wu X, Ragupathi G, Gathuru J, Koide F, Cheung NK, et al. Impact of minimal tumor burden on antibody response to vaccination. Cancer Immunol Immunother 2011; 60:621 - 7; http://dx.doi.org/10.1007/s00262-011-0975-9; PMID: 21267719
   PubMed Web of Science ®Google Scholar
• Wang XJ, Han G, Owens P, Siddiqui Y, Li AG. Role of TGF beta-mediated inflammation in cutaneous wound healing. J Investig Dermatol Symp Proc 2006; 11:112 - 7; http://dx.doi.org/10.1038/sj.jidsymp.5650004; PMID: 17069018
   PubMed Web of Science ®Google Scholar
• Martinez-Ferrer M, Afshar-Sherif AR, Uwamariya C, de Crombrugghe B, Davidson JM, Bhowmick NA. Dermal transforming growth factor-beta responsiveness mediates wound contraction and epithelial closure. Am J Pathol 2010; 176:98 - 107; http://dx.doi.org/10.2353/ajpath.2010.090283; PMID: 19959810
   PubMed Web of Science ®Google Scholar
• Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst 1998; 90:1529 - 36; http://dx.doi.org/10.1093/jnci/90.20.1529; PMID: 9790545
   PubMed Web of Science ®Google Scholar
• Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J Natl Cancer Inst 1998; 90:1609 - 20; http://dx.doi.org/10.1093/jnci/90.21.1609; PMID: 9811310
   PubMed Web of Science ®Google Scholar
• Lacchetti C, Ioannidis J, Guyatt G. Surprising results of randomized trials. Most Major Basic Science and Preclinical Promises for Effective Interventions Disapppoint in Clinical Trials. In: Guyatt G RD, Meade MO, Cook DJ, ed. Users’ Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice. New York: McGraw-Hill, 2008.
   Google Scholar
• Davis MR, Manning LS, Whitaker D, Garlepp MJ, Robinson BW. Establishment of a murine model of malignant mesothelioma. Int J Cancer 1992; 52:881 - 6; http://dx.doi.org/10.1002/ijc.2910520609; PMID: 1459729
   PubMed Web of Science ®Google Scholar
• Opitz OG, Harada H, Suliman Y, Rhoades B, Sharpless NE, Kent R, et al. A mouse model of human oral-esophageal cancer. J Clin Invest 2002; 110:761 - 9; PMID: 12235107
   PubMed Web of Science ®Google Scholar
• Lin KY, Guarnieri FG, Staveley-O’Carroll KF, Levitsky HI, August JT, Pardoll DM, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996; 56:21 - 6; PMID: 8548765
   PubMed Web of Science ®Google Scholar
• Dasch JR, Pace DR, Waegell W, Inenaga D, Ellingsworth L. Monoclonal antibodies recognizing transforming growth factor-beta. Bioactivity neutralization and transforming growth factor beta 2 affinity purification. J Immunol 1989; 142:1536 - 41; PMID: 2537357
   PubMed Web of Science ®Google Scholar